Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.60 ▲ +0.07
(+4.58%)
MKT CAP: $44.4M • VOL: 185.9K
52W L $1 52W H $3
ROARABLE / RQD
D • 45/100
PIOTROSKI
3 / 9
INMB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $50.0K | $14.0K | $155.0K |
| YoY Revenue Growth % | +257.1% | -91.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$47.4M | -$42.6M | -$29.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$46.0M | -$42.0M | -$30.0M |
| EBITDA (Normalized) | -$46.5M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$22.6M | -$33.4M | -$12.0M |
| Capital Expenditures (CapEx) | $1.0M | — | — |
| Free Cash Flow (FCF) | -$23.6M | -$33.4M | -$12.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $24.8M | $20.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $23.5M | $32.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INMB.